Intimation for change in details of Key Managerial Personnel for determining materiality of events or information and making disclosure to Stock Exchanges under Regulation 30 of SEBI Listing Regulations effective April 5, 2025
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Strides Pharma Science has notified stock exchanges about a change in the Key Managerial Personnel authorized to decide which company events qualify as 'material' and need to be disclosed under Regulation 30 of SEBI's Listing Regulations. This updated designation takes effect from April 5, 2025. The filing is part of routine compliance with listing rules that require companies to name specific officials responsible for materiality assessments. No business, financial, or operational changes are mentioned in this intimation. The announcement is purely an internal governance update related to disclosure responsibilities.
This is a routine regulatory compliance update with no direct impact on the company's financials, operations, or shareholder value. Investors should not read any operational or strategic signal into this filing — it simply updates who within the company is responsible for making timely disclosures to the exchanges.